Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Multi-targeting compounds offer advantages over single-targeting agents in anticancer drug discovery.
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is critical for angiogenesis and cancer progression.
• Histone Deacetylases (HDACs) regulate epigenetics and are implicated in angiogenesis and carcinogenesis.

Purpose of the Study:

• To design and synthesize novel diaryl-pyrazoline thiazolidinedione analogs targeting both VEGFR-2 and HDACs.
• To evaluate the in vitro and in vivo biological activities of these dual-targeting compounds.
• To identify potent lead compounds for further anticancer drug development.

Main Methods:

• Synthesis of nineteen novel VEGFR-2 and HDAC dual-targeting analogs.
• In vitro assays evaluating anti-angiogenic effects (HUVEC proliferation, migration, tube formation).
• In vivo chick chorioallantoic membrane (CAM) assay to assess anti-angiogenic potential.
• Cytotoxicity evaluation against various human cancer cell lines (MCF-7, K562, A549, HT-29).
• Enzyme inhibition assays for HDAC4 and molecular docking studies.

Main Results:

• Compound 14c emerged as a potent dual inhibitor of VEGFR-2 and HDAC.
• 14c demonstrated significant in vitro anti-angiogenic activity by inhibiting HUVEC functions.
• In vivo CAM assay confirmed 14c's ability to repress new capillary formation.
• 14c exhibited broad cytotoxicity against tested cancer cell lines and selective inhibition of HDAC4.
• Molecular docking studies corroborated the binding interactions with VEGFR-2 and HDAC4.

Conclusions:

• Compound 14c is a promising lead molecule for developing optimized multi-target anticancer agents.
• Dual inhibition of VEGFR-2 and HDAC represents a viable strategy for cancer therapy.
• Further optimization of 14c analogs could lead to enhanced potency and selectivity for improved anticancer efficacy.